Yagi Yuhki, Andoh Akira, Ogawa Atsuhiro, Bamba Shigeki, Tsujikawa Tomoyuki, Sasaki Masaya, Mitsuyama Keiichi, Fujiyama Yoshihide
Department of Medicine, Shiga University of Medical Science, Seta-Tukinowa, Otsu, Japan.
Ther Apher Dial. 2007 Oct;11(5):331-6. doi: 10.1111/j.1744-9987.2007.00495.x.
To elucidate the molecular mechanisms involved in the therapeutic effects of leukocytapheresis (LCAP), we performed microarray analysis for gene expression patterns in peripheral blood mononuclear cells (PBMCs) before and after LCAP therapy in patients with ulcerative colitis (UC). Four patients with UC were enrolled. PBMCs were isolated from peripheral venous blood obtained within 5 min before and after the first session of LCAP therapy. Cells were stimulated with IL-1beta for 12 h, and gene expression patterns were analyzed by an IntelliGene HS Human Expression Chip. The LCAP session reduced various genes, such as proinflammatory cytokines (IL-1alpha, IL-1beta, IL-6, IL-8, TNF-alpha, and IFN-gamma), cytokine receptors (IL-1R and IL-2Ralpha), chemokines, chemokine receptors, and intracellular signal transduction molecules. Genes which had increased after the LCAP session included those regulating anti-inflammatory cytokines and proteins (TGF-beta1 and IL-R antagonist), receptors for anti-inflammatory cytokines (IL-10R and IL-4R), growth factor receptors (IGF-R1, R2) and antioxidant proteins. Total changes in gene expression patterns after LCAP session were a combination of a decrease in pro-inflammatory genes and an enhancement of anti-inflammatory genes. These changes may explain some parts of the mechanisms by which LCAP improves clinical symptoms of UC patients.
为阐明白细胞去除术(LCAP)治疗效果所涉及的分子机制,我们对溃疡性结肠炎(UC)患者LCAP治疗前后外周血单个核细胞(PBMC)中的基因表达模式进行了微阵列分析。纳入了4例UC患者。在首次LCAP治疗前5分钟内及治疗后从外周静脉血中分离PBMC。细胞用IL-1β刺激12小时,并用IntelliGene HS人类表达芯片分析基因表达模式。LCAP治疗使多种基因减少,如促炎细胞因子(IL-1α、IL-1β、IL-6、IL-8、TNF-α和IFN-γ)、细胞因子受体(IL-1R和IL-2Rα)、趋化因子、趋化因子受体和细胞内信号转导分子。LCAP治疗后增加的基因包括调节抗炎细胞因子和蛋白质的基因(TGF-β1和IL-R拮抗剂)抗炎细胞因子的受体(IL-10R和IL-4R)、生长因子受体(IGF-R1、R2)和抗氧化蛋白。LCAP治疗后基因表达模式的总体变化是促炎基因减少和抗炎基因增强的综合结果。这些变化可能解释了LCAP改善UC患者临床症状机制的某些方面。